What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2023-03-01 compared with 2022-03-07 · 14 added, 36 removed, 472 unchanged (10% of the section changed)

161 unchanged sentences

larger number of customers.

2014, the Company ceased all previous manufacturing and sales activities.

Our revenues for the year ended December 31, 2017 consisted

of only consulting revenue, and our revenues for the year ended December 31, 2018 consisted of only $17,583 of grant revenue.

The Company’s

consulting revenues for the year ended December 31, 2017 were made to one customer, and those sales constituted 100% of total revenues

for that years.

At such time as the Company recommences active operations, no assurances can be given that the Company will be successful

in commercializing its products or expanding the number of customers purchasing its products and services.

The Company had $14,887 and

$7,000 in operating revenues, net of discounts for the years ended December 31, 2021 and 2020, respectively as they have commenced sales

of IsoPet ® .

Company’s consulting revenues relate to their commercializing of its products or expanding the number of customers purchasing its

products and services.

The Company had $36,499 and $14,887 in operating revenues, net of discounts for the years ended December 31, 2022

and 2021, respectively as they have commenced sales of IsoPet ® .

of the Company’s competitors have greater resources and experience than the Company has.

131 unchanged sentences

As a result of its assessment, management has determined that there is a material weakness due to the lack of segregation

of duties and, due to this material weakness, management concluded that, as of December 31, 2021 and 2020, the Company’s

internal control over financial reporting was ineffective.

of duties and, due to this material weakness, management concluded that, as of December 31, 2022 and 2021, the Company’s internal

control over financial reporting was ineffective.

This material weakness has the potential of adversely impacting the Company’s

7 unchanged sentences

reporting and disclosure controls and procedures.

Company may be unable to make timely license and patent payments

costs associated with existing and new technologies are significant;

however, the licensing contract with Battelle Pacific Northwest

Laboratory (“ Battelle ”) was re-negotiated to significantly reduce these costs.

Existing patent and license fees must

be paid for the Company to maintain rights to its technologies.

The Company would forfeit its exclusive rights to licensed technologies

in the event it fails to pay patent and rights fees in a timely fashion.

No assurance can be given that the Company will be able to continue

to pay license fees in the event it is unable to secure adequate working capital.

Battelle has advised the Company that if we did not

make a payment they would not attempt to relicense but would allow the patents to lapse.

The Company has decided to pursue additional

patents outside the Battelle contract based on exclusive proprietary manufacturing techniques developed by the Company.

Company’s patented or other technologies may infringe on other patents, which may expose it to costly litigation.

57 unchanged sentences

Company had 362,541,528 shares of common stock outstanding on March 1, 2023.

The Company also had outstanding on that date dilutive

securities consisting of preferred stock, restricted stock units, options, and warrants (collectively, “ Common Stock Equivalents ”)

that if they had been exercised and converted in full on March 1, 2022, would have resulted in the issuance of up to 69,287,379

additional shares of common stock.

The issuance of shares upon the exercise of the Common Stock Equivalents may result in substantial

dilution to each stockholder by reducing that stockholder’s percentage ownership of the Company’s total outstanding shares

of common stock.

The issuance of some or all those warrants and any exercise of those warrants will have the effect of further diluting

the percentage ownership of the Company’s other stockholders.

The Company also had outstanding on that date dilutive securities

consisting of preferred stock, restricted stock units, options, and warrants (collectively, “ Common Stock Equivalents ”)

that if they had been exercised and converted in full on March 1, 2023, would have resulted in the issuance of up to 64,762,379 additional

shares of common stock.

The issuance of shares upon the exercise of the Common Stock Equivalents may result in substantial dilution to

each stockholder by reducing that stockholder’s percentage ownership of the Company’s total outstanding shares of common

The issuance of some or all those warrants and any exercise of those warrants will have the effect of further diluting the percentage

ownership of the Company’s other stockholders.

sales of the Company’s securities, including sales following exercise or conversion of derivative securities, or the perception

108 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors